Arthneeti

Alpa Laboratories Share Price & Earnings Call Analysis

₹51.80-1.11% today
Market cap
₹109 Cr
P/E
26.85
ROE
8.38%
PEG
4.44
Price to sales
0.99
Debt to equity
0.01
52W high / low
₹90.3 / ₹46.5
Sales growth (5Y)
1.69%
EBITDA margin
-0.99%
Net profit margin
14.19%
Promoter holding
57.19%
Sales (last year)
₹111 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Alpa Laboratorie rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Alpa Laboratorie.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Alpa Laboratorie

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Alpa Laboratorie

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +27.3129.1625.4332.3927.3123.6121.4424.9426.1539.9219.1126.2629.05
Expenses +24.6919.9426.5729.0424.8820.1020.9121.6225.4139.7218.6828.5127.54
Operating Profit2.629.22-1.143.352.433.510.533.320.740.200.43-2.251.51
OPM %9.59%31.62%-4.48%10.34%8.90%14.87%2.47%13.31%2.83%0.50%2.25%-8.57%5.20%
Other Income +2.67-0.694.472.953.553.985.166.918.802.4811.943.060.91
Interest0.070.040.020.020.020.290.050.050.090.020.050.030.03
Depreciation0.100.530.280.490.660.520.540.530.550.580.550.670.65
Profit before tax5.127.963.035.795.306.685.109.658.902.0811.770.111.74
Tax %0.00%41.58%0.00%0.00%14.91%46.71%0.00%20.31%0.00%201.92%0.00%0.00%-9.20%
Net Profit +5.124.653.035.794.513.555.107.698.90-2.1211.770.111.90
EPS in Rs2.432.211.442.752.141.692.423.654.23-1.015.590.050.90

Financials of Alpa Laboratorie

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +565753636277859711293109110114
Expenses +515447565876809010185100105114
Operating Profit6377416811895-0
OPM %10%6%13%11%7%1%7%8%10%9%8%4%-0%
Other Income +12535504119142318
Interest2212110000000
Depreciation9613333121222
Profit before tax-5-3106533112016212616
Tax %4%-48%30%55%39%63%36%33%28%21%19%24%
Net Profit +-5-17331271413172012
EPS in Rs-2.45-0.673.261.201.340.480.883.456.705.987.989.275.53
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Alpa Laboratorie

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital21212121212121212121212121
Reserves6766727477777987101114131150162
Borrowings +23292411620062500
Other Liabilities +15132720182121332830255154
Total Liabilities127128144126122121121140155167182223238
Fixed Assets +73515151086797112121
CWIP0000001200000
Investments010121331495751757898118145
Other Assets +5411311897816558817182738471
Total Assets127128144126122121121140155167182223238

Financials of Alpa Laboratorie

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +8-2-2217-13-118-2109418
Cash from Investing Activity +-237-8-2-11-15-116-162-13-12
Cash from Financing Activity +47-6-159-5-105-43-5
Net Cash Flow1042-360-15-2054-07-71
Free Cash Flow6-3-3216-15-215-588-37
CFO/OP146%-92%-277%283%-263%102%324%15%123%155%85%466%

Financials of Alpa Laboratorie

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days130156234168153142105133124184138155
Inventory Days148761961311381059010281847392
Days Payable121912441401349998152781006397
Cash Conversion Cycle1571411871591571499783127168149150
Working Capital Days65-5204174208194125140118152135110
ROCE %0%10%8%6%3%5%7%9%12%15%16%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals